OneTouch Via: New diabetics device may make painful needles history

Results of the Market Acceptance Evaluation (MAE) study also demonstrated that physicians were more likely to recommend the innovative insulin delivery device to patients who are not at A1C goals or who are new to rapid-acting insulin (RAI) therapy.

[related-post]

Watch Video: What’s making news

The new OneTouch Via is a wearable, on-demand insulin delivery system in development that allows patients to discreetly deliver rapid-acting, or bolus, insulin at mealtimes by simply pressing two buttons on the device, accessible even through clothing. The thin, water-resistant patch can be worn continuously for up to three days, providing injection-free delivery of insulin when needed.

“People with diabetes can often feel embarrassment or discomfort when they need to inject insulin at mealtimes or when snacking. In a social situation, they may choose to miss a dose so they don’t have to take themselves out of the moment, but avoiding needed insulin doses may lead to serious health complications over time,” said Dr. Brian Levy.

Levy added, “Because patients in the study were empowered to dose discreetly with the OneTouch Via, they felt encouraged to dose more often – and ultimately, they reported missing fewer doses and better adherence to their treatment regimen.”

The healthcare professionals who assisted with the study noted that they preferred the OneTouch Via over both insulin pens and syringes (75 percent and 100 percent, respectively) and would be likely to recommend it to their patients. The doctors also reported that they would start patients on mealtime insulin earlier because of the ease of use of the OneTouch Via patch.

The study appears in American Diabetes Association (ADA) Conference.